Trial Profile
An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2019
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Roche
- 24 Sep 2019 Status changed from recruiting to discontinued.
- 29 Jul 2019 This trial is completed in United Kingdom according to Eudra
- 25 Jul 2011 This trial is recruiting in United Kingdom and has discontinued in Sweden.